How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor. Ho T, Tan BX, Lane D. Int J Mol Sci. 2019 Dec 18;21(1):13. doi: 10.3390/ijms21010013.

Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides. Diller DJ, Swanson J, Bayden AS, Brown CJ, Thean D, Lane DP, Partridge AW, Sawyer TK, Audie J. Molecules. 2019 Dec 14;24(24):4586. doi: 10.3390/molecules24244586.

Transmembrane signaling on a protocell: Creation of receptor-enzyme chimeras for immunodetection of specific antibodies and antigens. Su J, Kitaguchi T, Ohmuro-Matsuyama Y, Seah T, Ghadessy FJ, Hoon S, Ueda H. Sci Rep. 2019 Dec 3;9(1):18189. doi: 10.1038/s41598-019-54539-7.

Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci. Frosi Y, Inoue K, Ramlan SR, Lane DP, Watanabe T, Brown CJ. Sci Rep. 2019 Nov 29;9(1):17933. doi: 10.1038/s41598-019-54123-z.

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors. Kannan S, Partridge AW, Lane DP, Verma CS. Int J Mol Sci. 2019 Nov 28;20(23):5996. doi: 10.3390/ijms20235996.

Intratumour heterogeneity of p53 expression; causes and consequences. Xue Y, San Luis B, Lane DP. J Pathol. 2019 Nov;249(3):274-285. doi: 10.1002/path.5328.

Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase. Koh XY, Koh XH, Hwang LA, Ferrer FJ, Rahmat SAB, Lama D, Lane DP. Oncogene. 2019 Nov;38(48):7342-7356. doi: 10.1038/s41388-019-0946-8.

The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells. Mortensen ACL, Spiegelberg D, Brown CJ, Lane DP, Nestor M. Front Oncol. 2019 Sep 19;9:923. doi: 10.3389/fonc.2019.00923.

Development and application of a transcriptional sensor for detection of heterologous acrylic acid production in E. coli. Raghavan SS, Chee S, Li J, Poschmann J, Nagarajan N, Jia Wei S, Verma CS, Ghadessy FJ. Microb Cell Fact. 2019 Aug 19;18(1):139. doi: 10.1186/s12934-019-1185-y.

How to lose tumor suppression. Lane DP. Science. 2019 Aug 9;365(6453):539-540. doi: 10.1126/science.aay4319.

Characterization of Hydration Properties in Structural Ensembles of Biomolecules. Pradhan MR, Nguyen MN, Kannan S, Fox SJ, Kwoh CK, Lane DP, Verma CS. J Chem Inf Model. 2019 Jul 22;59(7):3316-3329. doi: 10.1021/acs.jcim.8b00453.

Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues In Vivo. Xue Y, Barker N, Hoon S, He P, Thakur T, Abdeen SR, Maruthappan P, Ghadessy FJ, Lane DP. Cancer Res. 2019 Jul 15;79(14):3595-3607. doi: 10.1158/0008-5472.CAN-18-3744.

Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties. Partridge AW, Kaan HYK, Juang YC, Sadruddin A, Lim S, Brown CJ, Ng S, Thean D, Ferrer F, Johannes C, Yuen TY, Kannan S, Aronica P, Tan YS, Pradhan MR, Verma CS, Hochman J, Chen S, Wan H, Ha S, Sherborne B, Lane DP, Sawyer TK. Molecules. 2019 Jun 20;24(12):2292. doi: 10.3390/molecules24122292.

Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles. Yuen TY, Brown CJ, Xue Y, Tan YS, Ferrer Gago FJ, Lee XE, Neo JY, Thean D, Kaan HYK, Partridge AW, Verma CS, Lane DP, Johannes CW. Chem Sci. 2019 May 30;10(26):6457-6466. doi: 10.1039/c9sc01456j.

Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly. Frosi Y, Usher R, Lian DTG, Lane DP, Brown CJ. BMC Biol. 2019 May 22;17(1):40. doi: 10.1186/s12915-019-0658-0.

Development and structural characterization of an engineered multi-copper oxidase reporter of protein-protein interactions. Sana B, Chee SMQ, Wongsantichon J, Raghavan S, Robinson RC, Ghadessy FJ. J Biol Chem. 2019 Apr 26;294(17):7002-7012. doi: 10.1074/jbc.RA118.007141.

p53: updates on mechanisms, biology and therapy (II). Lane DP, Verma CS. J Mol Cell Biol. 2019 Apr 1;11(4):265-266. doi: 10.1093/jmcb/mjz018.

Corrigendum to 'Understanding p53 functions through p53 antibodies'. Sabapathy K, Lane DP. J Mol Cell Biol. 2019 Dec 19;11(12):1105. doi: 10.1093/jmcb/mjz110.

Understanding p53 functions through p53 antibodies. Sabapathy K, Lane DP. J Mol Cell Biol. 2019 Apr 1;11(4):317-329. doi: 10.1093/jmcb/mjz010.

Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides. Pal A, Neo K, Rajamani L, Ferrer FJ, Lane DP, Verma CS, Mortellaro A. Sci Rep. 2019 Mar 20;9(1):4913. doi: 10.1038/s41598-019-41211-3.

Radiation-induced astrocyte senescence is rescued by Δ133p53. Turnquist C, Beck JA, Horikawa I, Obiorah IE, Von Muhlinen N, Vojtesek B, Lane DP, Grunseich C, Chahine JJ, Ames HM, Smart DD, Harris BT, Harris CC. Neuro Oncol. 2019 Mar 18;21(4):474-485. doi: 10.1093/neuonc/noz001.

p53: updates on mechanisms, biology and therapy (I). Lane DP, Verma CS. J Mol Cell Biol. 2019 Mar 1;11(3):185-186. doi: 10.1093/jmcb/mjz017.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX. Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x.

Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket. Pradhan MR, Siau JW, Kannan S, Nguyen MN, Ouaray Z, Kwoh CK, Lane DP, Ghadessy F, Verma CS. Nucleic Acids Res. 2019 Feb 28;47(4):1637-1652. doi: 10.1093/nar/gky1314.

Structural insights reveal a recognition feature for tailoring hydrocarbon stapled-peptides against the eukaryotic translation initiation factor 4E protein. Lama D, Liberatore AM, Frosi Y, Nakhle J, Tsomaia N, Bashir T, Lane DP, Brown CJ, Verma CS, Auvin S. Chem Sci. 2019 Jan 7;10(8):2489-2500. doi: 10.1039/c8sc03759k.


A novel λ integrase-mediated seamless vector transgenesis platform for therapeutic protein expression. Makhija H, Roy S, Hoon S, Ghadessy FJ, Wong D, Jaiswal R, Campana D, Dröge P. Nucleic Acids Res. 2018 Sep 19;46(16):e99. doi: 10.1093/nar/gky500.

Rapid colorimetric detection of p53 protein function using DNA-gold nanoconjugates with applications for drug discovery and cancer diagnostics. Assah E, Goh W, Zheng XT, Lim TX, Li J, Lane D, Ghadessy F, Tan YN. Colloids Surf B Biointerfaces. 2018 Sep 1;169:214-221. doi: 10.1016/j.colsurfb.2018.05.007.

Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive. Keszei M, Record J, Kritikou JS, Wurzer H, Geyer C, Thiemann M, Drescher P, Brauner H, Köcher L, James J, He M, Baptista MA, Dahlberg CI, Biswas A, Lain S, Lane DP, Song W, Pütsep K, Vandenberghe P, Snapper SB, Westerberg LS. J Clin Invest. 2018 Aug 31;128(9):4115-4131. doi: 10.1172/JCI64772.

A novel molecular rotor facilitates detection of p53-DNA interactions using the Fluorescent Intercalator Displacement Assay. Goh WL, Lee MY, Lim TX, Chua JS, Brenner S, Ghadessy FJ, Teo YN. Sci Rep. 2018 Aug 28;8(1):12946. doi: 10.1038/s41598-018-31197-9.

Guardian of Genome Editing. Ho T, Lane DP. CRISPR J. 2018 Aug;1:258-260. doi: 10.1089/crispr.2018.29021.dal.

The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors. Spiegelberg D, Mortensen AC, Lundsten S, Brown CJ, Lane DP, Nestor M. Cancer Res. 2018 Sep 1;78(17):5084-5093. doi: 10.1158/0008-5472.CAN-18-0440.

Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding. Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SK. Sci Rep. 2018 Jul 18;8(1):11110. doi: 10.1038/s41598-018-29097-z.

Mass Spectrometry Reveals the Direct Action of a Chemical Chaperone. Gault J, Lianoudaki D, Kaldmäe M, Kronqvist N, Rising A, Johansson J, Lohkamp B, Laín S, Allison TM, Lane DP, Marklund EG, Landreh M. J Phys Chem Lett. 2018 Jul 19;9(14):4082-4086. doi: 10.1021/acs.jpclett.8b01817.

Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function. Lau SY, Siau JW, Sobota RM, Wang CI, Zhong P, Lane DP, Ghadessy FJ. Protein Eng Des Sel. 2018 Jul 1;31(7-8):301-312. doi: 10.1093/protein/gzy018.

When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. Bradbury ARM, Trinklein ND, Thie H, Wilkinson IC, Tandon AK, Anderson S, Bladen CL, Jones B, Aldred SF, Bestagno M, Burrone O, Maynard J, Ferrara F, Trimmer JS, Görnemann J, Glanville J, Wolf P, Frenzel A, Wong J, Koh XY, Eng HY, Lane D, Lefranc MP, Clark M, Dübel S. MAbs. 2018 May/Jun;10(4):539-546. doi: 10.1080/19420862.2018.1445456.

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5.

Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. Ladds MJGW, Pastor-Fernández A, Popova G, van Leeuwen IMM, Eng KE, Drummond CJ, Johansson L, Svensson R, Westwood NJ, McCarthy AR, Tholander F, Popa M, Lane DP, McCormack E, McInerney GM, Bhatia R, Laín S. PLoS One. 2018 Apr 23;13(4):e0195956. doi: 10.1371/journal.pone.0195956.

Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges. Sawyer TK, Partridge AW, Kaan HYK, Juang YC, Lim S, Johannes C, Yuen TY, Verma C, Kannan S, Aronica P, Tan YS, Sherborne B, Ha S, Hochman J, Chen S, Surdi L, Peier A, Sauvagnat B, Dandliker PJ, Brown CJ, Ng S, Ferrer F, Lane DP. Bioorg Med Chem. 2018 Jun 1;26(10):2807-2815. doi: 10.1016/j.bmc.2018.03.008.

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3.

Effect of VH-VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding. Ling WL, Lua WH, Poh JJ, Yeo JY, Lane DP, Gan SK. Front Immunol. 2018 Mar 12;9:469. doi: 10.3389/fimmu.2018.00469.

p53 isoforms regulate premature aging in human cells. von Muhlinen N, Horikawa I, Alam F, Isogaya K, Lissa D, Vojtesek B, Lane DP, Harris CC. Oncogene. 2018 May;37(18):2379-2393. doi: 10.1038/s41388-017-0101-3.

Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase. Costeira-Paulo J, Gault J, Popova G, Ladds MJGW, van Leeuwen IMM, Sarr M, Olsson A, Lane DP, Laín S, Marklund EG, Landreh M. Cell Chem Biol. 2018 Mar 15;25(3):309-317.e4. doi: 10.1016/j.chembiol.2017.12.012.

The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding. Lua WH, Ling WL, Yeo JY, Poh JJ, Lane DP, Gan SK. Sci Rep. 2018 Jan 15;8(1):718. doi: 10.1038/s41598-017-18892-9.

Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine. Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP, Sabapathy K. Cell Rep. 2018 Jan 2;22(1):299-312. doi: 10.1016/j.celrep.2017.11.112.

Evidence for allosteric effects on p53 oligomerization induced by phosphorylation. Muller P, Chan JM, Simoncik O, Fojta M, Lane DP, Hupp T, Vojtesek B. Protein Sci. 2018 Feb;27(2):523-530. doi: 10.1002/pro.3344.

Laccase-Catalyzed Synthesis of Low-Molecular-Weight Lignin-Like Oligomers and their Application as UV-Blocking Materials. Lim J, Sana B, Krishnan R, Seayad J, Ghadessy FJ, Jana S, Ramalingam B. Chem Asian J. 2018 Feb 2;13(3):284-291. doi: 10.1002/asia.201701573.

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Sabapathy K, Lane DP. Nat Rev Clin Oncol. 2018 Jan;15(1):13-30. doi: 10.1038/nrclinonc.2017.151.


  • Zheng S, Koh XY, Goh HC, Rahmat SAB, Hwang LA and Lane DP. (2017). Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity . Cancer Research, 77, 4342-4354.

  • Thean D, Ebo JS, Luxton T, Lee XC, Yuen TY, Ferrer FJ, Johannes CW, Lane DP, Brown CJ. Enhancing (2017). Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery . Sci Rep., 11;7 (1), 1763.

  • Cheok CF, Lane DP. Cold Spring Harb Perspect Med. (2017) . Exploiting the p53 Pathway for Therapy. 2017 Mar 1;7(3). Review

  • Goh HC, Sobota RM, Ghadessy FJ, Nirantar S. (2017). Going native: Complete removal of protein purification affinity tags by simple modification of existing tags and proteases. Protein Expr Purif. 2017 Jan;129:18-24.

  • Tan BX, Liew HP, Chua JS, Ghadessy FJ, Tan YS, Lane DP, Coffill CR. (2017). Anatomy of Mdm2 and Mdm4 in evolution . J Mol Cell Biol. 2017 Jan 10. [Epub ahead of print] Review.

  • 2016

  • Siau JW, Coffill CR, Zhang WV, Tan YS, Hundt J, Lane D, Verma C, and Ghadessy F. (2016). Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens   . Sci Rep., 6, 33972.

  • Xue Y, Raharja A, Sim W, Wong ES, Rahmat SA, Lane DP. (2016). The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage . Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.374. [Epub ahead of print]

  • Wei SJ, Chee S, Yurlova L, Lane D, Verma C, Brown C, Ghadessy F. (2016). Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.   Oncotarget. 2016 Apr 4. doi: 10.18632/oncotarget.8572. [Epub ahead of print]

  • Tan YS, Lane DP, Verma CS. (2016). Stapled peptide design: principles and roles of computation.  Drug Discov Today. 2016 Jun 18. pii: S1359-6446(16)30230-6.

  • Coffill CR, Lee AP, Siau JW, Chee SM, Joseph TL, Tan YS, Madhumalar A, Tay BH, Brenner S, Verma CS, Ghadessy FJ, Venkatesh B, Lane DP. (2016). The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humansGenes Dev. 2016 Feb 1;30(3):281-92.

  • Kannan S, Lane DP, Verma CS. (2016). Long range recognition and selection in IDPs: the interactions of the C-terminus of p53. Sci Rep. 2016; 6: 23750.

  • 2015

  • Geng J, Goh WL, Zhang C, Lane DP, Liu B, Ghadessy G, Tan YN. (2015).  A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells. Journals of Materials Chemistry B, 2015, 3, 5933-5937.

  • Chua JS, Liew HP, Guo L, Lane DP. (2015). Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish.  Oncogene. 2015 Mar 9. doi: 10.1038/onc.2015.57. [Epub ahead of print]

  • Tan BX, Brown CJ, Ferrer FJ, Yuen TY, Quah ST, Chan BH, Jansson AE, Teo HL, Nordlund P, Lane DP. (2015). Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays . Sci Rep., 5, 12116.

  • 2014

  • L Li, DSW Ng, W-C Mah, FF Almeida, SA Rahmat, VK Rao, SC Leow, F Laudisi, MT Peh, AM Goh, JSY Lim, GD Wright, A Mortellaro, R Taneja, F Ginhoux, CG Lee, PK Moore, DP Lane. (2014). A unique role for p53 in the regulation of M2 marcophage polarisation. Cell Death Differ. 2014 Dec 19. doi: 10.1038/cdd.2014.212. [Epub ahead of print]

  • Kian Hoe Khoo, Chandra S. Verma & David P. Lane (2014). Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Feb 28;13(3):217-36.

  • 2013

  • Lama D, Quah ST, Verma CS, lakshminarayanan R, Beuerman RW, Lane DP, Brown CJ (2013). Rational optimization of conformational effects induced by hydrocarbon staples in peptides and their binding interfaces . Sci Rep., 13 (3), 3451.

  • Brown CJ, Quah ST, Jong J, Goh AM, Chiam PC, Khoo KH, Choong ML, Lee MA, Yurlova L, Zolghadr K, Joseph TL, Verma CS, Lane DP (2013). Stapled peptides with improved potency and specificity that activate p53 . ACS Chem Biol., 15;8 (3), 506-12.

  • Tan, B.X., Khoo, K.H., Lim, T.M., Lane, D.P. (2013). High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia .  Oncotarget. 2013 Nov 22.

  • Mondal, A.M., Horikawa, I., Pine, S.R., Fujita, K., Morgan, K.M., Vera, E., Mazur, S.J., Appella, E., Vojtesek, B., Blasco, M.A., Lane, D.P., Harris, C.C. (2013). p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest. 2013 Dec 2;123(12):5247-57.

  • Wong, J.S., Warbrick, E., Vojtesk, B., Hill, J., Lane, D.P. (2013). Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth Oncotarget. 2013 Jul;4(7):1019-36.

  • Tao, T., Shi, H., Guan, Y., Huang, D., Chen, Y., Lane, D.P., Chen, J., Peng, J. (2013). Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation . Cell Res. 2013 Jan 29.

  • 2012 and earlier

  • Guo L, Liew HP, Camus S, Goh AM, Chee LL, Lunny DP, Lane EB, Lane DP (2012).   Oncogene. 2012 Oct 15.

  • Coffill, C.R., Muller, P.A., Oh, H.K., Neo, S.P., Hogue, K.A., Cheok, C.F., Vousden, K.H., Lane, D.P., Blackstock, W.P., Gunaratne, J. (2012). Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasionEMBO Rep. 2012 Jun 29: 13(7):638-44.

  • Muller, P.A., Trinidad, A.G., Timpson, P., Morton, J.P., Zanivan, S., van den Berghe, P.V., Nixon, C., Karim, S.A., Caswell, P.T., Noll, J.E., Coffill, C.R., Lane, D.P., Sansom, O.J., Neilsen, P.M., Norman, J.C., Vousden, K.H. (2012). Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene. 2013 Mar 7;32(10):1252-65.

  • Goh, A.M., Lim, C.Y., Chiam, P.C., Li, L., Mann, M.B., Mann, K.M., Menendez, S. and Lane, D.P. (2012). Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity . Proc Natl Acad Sci U S A. 109(5), 1685-90.

  • Lane, D.P., Madhumalar, A., Lee, A.P., Tay, B.H., Verma, C., Brenner, S, and Venkatesh B. (2011). Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish . Cell Cycle. 10(24), 4272-9.

  • Dastidar, S.G., Raghunathan, D., Nicholson, J., Hupp, T.R., Lane, D.P. and Verma, C.S. (2011). Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation Cell Cycle. 10(1), 82-9.

  • See, H.Y. and Lane, D.P. (2010).  A novel unstructured scaffold based on 4EBP1 enables the functional display of a wide range of bioactive peptides . J Mol Biol. 404(5), 819-31.

  • Cheok, C.F., Kua, N., Kaldis, P. and Lane, D.P. (2010). Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ. 17(9), 1486-500

  • Lane, D.P., Cheok, C.F., Brown, C., Madhumalar, A., Ghadessy, F.J. and Verma, C. (2010). Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle. 9(3), 540-547.

  • Wan, K.F., Wang, S., Brown, C.J., Yu, V.C., Entzeroth, M., Lane, D.P. and Lee, M.A. (2009). Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL. Cell Cycle. 8(23), 3943-52.

  • Brown, C.J., Dastidar, S.G., See, H.Y., Coomber, D.W., Ortiz-Lombardía, M., Verma, C. and Lane, D.P. (2009). Rational Design and Biophysical Characterization of Thioredoxin-Based Aptamers: Insights into Peptide Grafting. J Mol Biol. 395(4), 871-83.

  • Brown, C.J., Verma, C.S., Walkinshaw, M.D. and Lane, D.P. (2009). Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site. Cell Cycle. 8, 1905-1911.

  • Chen, J., Ng, S.M., Chang, C., Zhang, Z., Bourdon, J.C., Lane, D.P. and Peng, J. (2009). p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish.  Genes Dev. 2009. 23: 278-90

  • Lain, S., Hollick, J.J., Campbell, J., Staples, O.D., Higgins, M., Aoubala, M., McCarthy, A., Appleyard, V., Murray, K.E., Baker, L., Thompson, A., Mathers, J., Holland, S.J., Stark, M.J.R., Pass, G., Woods, J., Lane, D.P. and Westwood, N.J. (2008). Discovery, in vivo activity and mechanism of action of a small-molecule p53 activator.   Cancer Cell. 2008. 13:454-63.

  • Lee, K.C., Goh, W.L., Xu, M., Kua, N., Lunny, D., Wong, J.S., Coomber, D., Vojtesek, B., Lane, E.B. and Lane, D.P. (2008). Detection of the p53 response in zebrafish embryos using new monoclonal antibodies.  Oncogene. 2008. 27 (5): 629-40

  • Dey, A., Wong, E.T., Cheok, C.F., Tergaonkar, V. and Lane, D.P. (2008). R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 2008. 15: 263-73.

  • Cheok CF, Dey A, Lane DP. (2007). Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.  Mol Cancer Res. 2007. 5(11):1133-45.

  • Stevenson, L.F., Sparks, A., Allende-Vega, N., Xirodimas, D.P., Lane, D.P. and Saville, M.K. (2007). The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 2007. 26:976-86.

  • Chen, J., Ruan, H., Ng, S.M., Gao, C., Soo, H.M., Wu, W., Zhang, Z., Wen, Z., Lane, D.P. and Peng, J. (2005). Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev. 2005. 19:2900-11.

  • Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K. and Lane, D.P. (2005). p53 isoforms can regulate p53 transcriptional activity.   Genes Dev. 2005. 19:2122-37.

  • Kontopidis, G., Wu, S.Y., Zheleva, D.I., Taylor, P., McInnes, C, Lane, D.P., Fischer, P.M. and Walkinshaw, M.D. (2005). From the Cover: Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A. 2005. 102(6):1871-6.

  • Xirodimas, D.P., Saville, M.K., Bourdon, J.C., Hay, R.T. and Lane, D.P. (2004). Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell. 2004. 9:83-97.

  • Bottger, A., Bottger, V., Sparks, A., Liu,, W.L., Howard, S. and Lane, D.P.  (1997). Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997. 7:860-869.

  • Hupp, T.R., Sparks, A. and Lane, D.P. (1995). Small peptides activate the latent sequence specific DNA binding function of p53.   Cell. 1995. 83:237-245.

  • Lu, X. and Lane, D.P. (1993). Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell. 1993. 75:765-778.

  • Hall, P.A., McKee, P.H., Menage, H du P., Dover, R. and Lane, D.P. (1993). High levels of p53 protein in UV irradiated normal human skin. Oncogene. 1993. 8:203-207.

  • Lane, D.P. (1992). Cancer - p53, Guardian of the Genome. Nature. 1992. 358:15-16.

  • Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992). Regulation of the DNA binding function of p53. Cell. 1992. 71:875-886.

  • Bartek, J. Bartkova, J. Vojtesek, B. Staskova, Z. Lukas, J. Rejthar, A. Kovarik, J. Midgley, C.A. Gannon, J.V. and Lane, D.P. (1991). Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991. 6:1699-1703.

  • Iggo, R. Gatter K.G. Bartek, J., Lane, D. and Harris, A.L. (1990) . Increased expression of mutant forms of the p53 oncogene in primary lung cancer.   Lancet. 1990. 335:675-679.

  • Yewdell, J.W., Gannon, J.V. and Lane, D.P. (1986). Monoclonal antibody analysis of p53 expression in normal and transformed cells.  J.Virol. 1986. 59:444-452.

  • Lane, D.P. and Crawford, L.V. (1979). SV40 T antigen is bound to a host protein in V40 transformed cells.  Nature. 1979. 278:261-263.

    Please click here   for a full list of David Lane's publications.

    Check here for David Lane's full Pubmed entry